MedTrace Logo

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

NCT02061449 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2018-12-24

No results posted yet for this study

Summary

This study evaluates the safety and tolerability of the addition of immunostimulatory therapy consisting of focal radiation with or without the Toll-like receptor (TLR) agonist Poly ICLC in patients with cutaneous T-cell lymphoma (CTCL) receiving concurrent therapy with the histone deacetylase inhibitor (HDACI) Romidepsin.

Conditions

  • Cutaneous T-cell Lymphoma

Interventions

DRUG

Romidepsin

DRUG

Poly ICLC

RADIATION

Focal lesional radiation

Sponsors & Collaborators

Principal Investigators

  • Catherine Diefenbach, MD · NYU Langone Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2018-11-05
Completion
2018-11-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02061449 on ClinicalTrials.gov